Skip to content

Ketamine for anxiety: all studies

Page 3 of 19: studies 21 to 30 of 187, newest first. Back to the ketamine for anxiety overview

Research

S-ketamine mitigates paclitaxel-induced pain-related anxiety-like behavior through downregulation of mGluR5 and activation of the BDNF/TrkB signaling pathway

Frontiers in Neurology April 23, 2026 Jing Cao, ZiYuan Wang, GeGe Lv et al.

Background Paclitaxel (PTX), a broad-spectrum anti-tumor drug, is extensively employed as a first-line chemotherapy for solid tumors, including lung and breast cancers. However, it induces chemotherapy-related pain and anxiety in over 53% of patients. S-ketamine, the S-enantiomer of ketamine, exerts rapid antidepressant effects. In this study, we established a PTX model to examine the effects...

Inulin ameliorates chronic ketamine-induced anxiety-like behaviors and impairments in spatial learning and memory: involvement of gut microbiota, microbial metabolite short-chain fatty acids, and the BDNF-TrkB-ERK1/2-CREB pathway

Frontiers in Microbiology April 7, 2026 Zhilong Xu, Jie Zhang, Canrun Hu et al.

Chronic ketamine exposure results in psychotic and cognitive symptoms that resemble those found in patients with schizophrenia. Emerging evidence suggests that patients with schizophrenia exhibit gut microbiota dysbiosis and decreased levels of short-chain fatty acids (SCFAs) and BDNF, which are related to the severity of psychotic and cognitive symptoms. Dietary inulin can regulate gut...

Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial

Medicine March 6, 2026 Hongfei Xiong, Yingxue Xu, Jiayi Liu et al.

This study demonstrates the efficacy of single-dose esketamine regimens, administered orally (ED95: 8.2125 mg/kg; 95% CI: 7.4250-8.4597 mg/kg) and intranasally (ED95: 2.1770 mg/kg; 95% CI: 2.0952-2.1958 mg/kg), in mitigating preoperative anxiety within a pediatric population. These findings highlight the safety and efficacy of esketamine for this patient group.

A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program.

Journal of Palliative Medicine March 1, 2026 Robert K Horowitz, William E Rosa, Ali John Zarrabi et al.

Psychospiritual distress (PSD) causes profound suffering in people with serious illness, yet treatment options are few and evidence of their efficacy is modest. Although high-level evidence is limited, decades of preliminary research suggest that psychedelic-assisted psychotherapy (PAP), including ketamine-assisted psychotherapy (KAP), may alleviate the anxiety, depression, and existential...

At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis

Research Square February 11, 2026 Jack Swain, Davis Carter, Leonardo Vando preprint

Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult population annually, and is characterized by intrusive symptoms, avoidance, negative cognitive and mood alterations, and hyperarousal following trauma exposure. Ketamine shows promise as a treatment for PTSD in preliminary trials, though real-world...

Effect of subanesthetic dose esketamine on anxiety and depression in patients with breast cancer after surgery: a randomized controlled, double-blind study.

BMC Psychiatry February 9, 2026 Song-Yuan Liu, Rong Huang, Zhuang Liu et al.

BACKGROUND: In recent years, evidence has suggested that subanesthetic doses of esketamine may have beneficial effects on perioperative anxiety and depression. Concurrently, various factors contribute to a high incidence of perioperative depression and anxiety in the breast cancer patient population. This study aimed to explore the impact of preoperative induction and intraoperative maintenance...

Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression: A Qualitative Exploratory Study

Brain Sciences February 7, 2026 Miriam Olivola, Tiziano Prodi, Giada Versaci et al. 2 citations

Background/Objectives: Esketamine-related dissociation is a transient, pharmacologically induced altered state that differs from the trait-like pathological dissociation typically observed in trauma-related conditions. While most studies have quantified these effects using the Clinician-Administered Dissociative States Scale (CADSS), patients' subjective phenomenology and meaning-making remain...

DOI: 10.3390/brainsci16020196 (opens in new tab) Anxiety Dissociative experiences scale Dissociation chemistry Distress +15

A systematic review of ketamine's anxiolytic potential in rodent behavioral models of anxiety and PTSD.

Pharmacology, biochemistry, and behavior February 2026 Alena Lemeshova, Kaya A Patel, Alexander J Bloom et al.

Ketamine, a nonselective NMDA-receptor antagonist, is an emerging therapeutic for treatment-resistant depression and could also be a promising treatment for anxiety and post-traumatic stress disorders. However, preclinical studies in these areas lack methodological standardization, limiting clinical translatability. This review evaluates ketamine's anxiolytic potential in rodents by examining...

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Journal of the Royal Society of New Zealand February 1, 2026 Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...

A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program

Journal of Military Veteran and Family Health February 1, 2026 Ian Stefanuk, Kaitlin Chivers-Wilson, Rakesh Jetly et al.

Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans, and the presence of multiple conditions requires innovative treatment approaches. The Newly Institute in Calgary, Alberta, Canada, has introduced a novel intervention combining sublingual ketamine therapy with a medically managed transdiagnostic...

DOI: 10.3138/jmvfh-2025-0009 (opens in new tab) Anxiety disorder Checklist Depression economics Intervention counseling +7